Genmab Streamlines Portfolio by Cutting Early-Stage Oncology Assets

Portfolio Optimization:
Genmab has decided to discontinue three early-stage oncology assets to focus on its late-stage programs, including an antibody-drug conjugate (ADC) from its purchase of ProfoundBio.

Strategic Focus:
This move is part of Genmab's strategy to prioritize its Phase 3 projects and upcoming milestones, aiming to concentrate resources on more promising candidates.

ProfoundBio Acquisition:
Genmab acquired ProfoundBio in an all-cash transaction to augment its cancer pipeline with a portfolio of ADCs, including rinatabart sesutecan (Rina-S), which is in a Phase I/II clinical trial for ovarian cancer.

Industry Context:
This decision aligns with broader industry trends where companies like Sanofi have also reallocated resources from clinical-stage oncology programs to other areas, such as immunology.

Genmab's Strategy:
By focusing on late-stage projects, Genmab aims to accelerate the development and commercialization of its most promising oncology assets.